Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark D Fleming

Showing results (11-20 of 215) with videos related to

Pageof 22
Sort By:
The Journal of Clinical Investigation|November 29, 2012
Mitochondrial heme: an exit strategy at lastMark D Fleming, Iqbal Hamza
Hematology/Oncology Clinics of North America|March 5, 2014
Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approachesPaul J Schmidt, Mark D Fleming
American Journal of Clinical Pathology|March 1, 2020
Histologic and Laboratory Characteristics of Symptomatic and Asymptomatic Castleman Disease in the Pediatric PopulationKaren M Chisholm, Mark D Fleming
The Journal of Clinical Investigation|November 25, 2010
A tincture of hepcidin cures all: the potential for hepcidin therapeuticsThomas B Bartnikas, Mark D Fleming
Haematologica|October 14, 2011
Hemojuvelin is essential for transferrin-dependent and transferrin-independent hepcidin expression in miceThomas B Bartnikas, Mark D Fleming
Hematology/Oncology Clinics of North America|July 28, 2014
Sideroblastic anemia: diagnosis and managementSylvia S Bottomley, Mark D Fleming
American Journal of Hematology|March 31, 2012
Transgenic HFE-dependent induction of hepcidin in mice does not require transferrin receptor-2Paul J Schmidt, Mark D Fleming
Current Opinion in Chemical Biology|February 19, 2013
Heme transport and erythropoiesisXiaojing Yuan, Mark D Fleming, Iqbal Hamza
Muscle & Nerve|January 5, 2022
Hereditary myopathies associated with hematological abnormalitiesGrayson Beecher, Mark D Fleming, Teerin Liewluck
Biochimica Et Biophysica Acta|February 7, 2012
Murine mutants in the study of systemic iron metabolism and its disorders: an update on recent advancesThomas B Bartnikas, Mark D Fleming, Paul J Schmidt
Pageof 22

Showing results (11-20 of 215) with videos related to

Sort By:
Pageof 22
The Journal of Clinical Investigation|November 29, 2012
Mitochondrial heme: an exit strategy at lastMark D Fleming, Iqbal Hamza
Hematology/Oncology Clinics of North America|March 5, 2014
Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approachesPaul J Schmidt, Mark D Fleming
American Journal of Clinical Pathology|March 1, 2020
Histologic and Laboratory Characteristics of Symptomatic and Asymptomatic Castleman Disease in the Pediatric PopulationKaren M Chisholm, Mark D Fleming
The Journal of Clinical Investigation|November 25, 2010
A tincture of hepcidin cures all: the potential for hepcidin therapeuticsThomas B Bartnikas, Mark D Fleming
Haematologica|October 14, 2011
Hemojuvelin is essential for transferrin-dependent and transferrin-independent hepcidin expression in miceThomas B Bartnikas, Mark D Fleming
Hematology/Oncology Clinics of North America|July 28, 2014
Sideroblastic anemia: diagnosis and managementSylvia S Bottomley, Mark D Fleming
American Journal of Hematology|March 31, 2012
Transgenic HFE-dependent induction of hepcidin in mice does not require transferrin receptor-2Paul J Schmidt, Mark D Fleming
Current Opinion in Chemical Biology|February 19, 2013
Heme transport and erythropoiesisXiaojing Yuan, Mark D Fleming, Iqbal Hamza
Muscle & Nerve|January 5, 2022
Hereditary myopathies associated with hematological abnormalitiesGrayson Beecher, Mark D Fleming, Teerin Liewluck
Biochimica Et Biophysica Acta|February 7, 2012
Murine mutants in the study of systemic iron metabolism and its disorders: an update on recent advancesThomas B Bartnikas, Mark D Fleming, Paul J Schmidt
Pageof 22